Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (10717)	2/29/2004 3:46:48 PM
From: quidditch	Read Replies (1) \| Respond to of 52153

Mike, Rick, sales, Peter and others follow this closely. I recall estimates that indiplon NDA would be filed anywhere from six months to one year after FDA action on estorra. I just checked the NBIX website and (somewhat shockingly) it does not appear to have been updated recently: still refers to an NDA by year-end 2003 and reports on progress on the malignant glioma candidate (still in NBIX of course but to be out-licensed or otherwise disposed of). My guess is that, with multiple P3s concluding, it will be by the end of this year. A technical question: in the IR and MR forms of indiplon, can that be encompassed by one application or do the two release formulations require separate NDAs? quid

To: Michael Young who wrote (10717)	2/29/2004 9:55:46 PM
From: Harold Engstrom	Read Replies (2) \| Respond to of 52153

Arformoterol and rest of pipe can be added to pending xop MDI... Rick, do you have any opinion about SEP225382 for migraines... H